Assessment of Transforming Growth Factor β1 and DNA Cell Cycle in Egyptian Patients with Chronic Hepatitis-C Virus and Hepatocellular Carcinoma

Authors(4) :-Zahran Faten, El- Emshaty Hoda, Gouida Mona, Hussien Mohamed

Hepatocellular carcinoma (HCC) is the end-stage of chronic liver diseases (CLDs). The main aetiologies of CLDs are chronic hepatitis C virus (HCV) infection. The aim of this work was to evaluate diagnostic value of TGF-β1 in patients with chronic liver disease (CLD) Fibrosis, HCC and healthy individuals. The present study included 51 patients with Fibrosis (F2-F4), 30 Hepatocellular Carcinoma (HCC) patients, in addition 40 normal healthy individuals were enrolled in this study as control group. AFP and CEA were estimated in all groups. TGF-β1 and DNA Cell Cycle were estimated using Flow Cytometry technique. Results from this study revealed that there was high significance difference in APRI ratio, FIB-4 ratio between HCC, Fibrosis comparing with Control group (p<0.05), also there was high prevalence TGF-β1 in HCC patients comparing with both Fibrosis and healthy control group (P<0.005). In our study G2/M phase DNA Cell cycle was increased significantly in both HCC and Fibrosis patients. Based on our observation in this study TGF-β1 has diagnostic value importance in assessment of hepatocellular carcinoma.

Authors and Affiliations

Zahran Faten
Department of Chemistry, Zagazig University, Egypt
El- Emshaty Hoda
Gastroenterology Center, Mansoura University, Egypt
Gouida Mona
Mansoura Children Hospital, Mansoura University, Egypt
Hussien Mohamed
Mansoura Chest Hospital, Egypt

Hepatocellular Carcinoma (HCC), Transforming growth Factor beta1 TGF-β1, Alpha Feto Protein (AFP), Carcinoembryonic Antigen (CEA)

  1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M, Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244: 359-362, 1989.
  2. Lehman EM, Soliman AS, Ismail K, et al, Patterns of hepatocellular carcinoma incidence in Egypt from a population-based Cancer registry. Hepatol Res 38:465-73, 2008.
  3. Kandeel A, Genedy M, El-Refai S, Funk LA, Fontanet A, and Talaat M, The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int.; 37: 45–53, 2017.
  4. Roncalli M, Park YN, di Tommaso L, Histopathological classification of hepatocellular carcinoma. Dig. Liver Dis. 42, S228–S234, 2010.
  5. Okuda K, Hepatocellular carcinoma. J. Hepatol. 32, 225–237, 2000.
  6. Hanahan D, Weinberg RA, Hallmarks of cancer: The next generation. Cell. 144, 646–674, 2011.
  7. Marrero J, Feng Z, Wang Y, Nguyen M, Befeler A, Roberts LR, et al, Alfa-feto protein, des-gamma carboxy prothrombin, and lectin-bound alpha-feto protein in early hepatocellular carcinoma. Gastroenterology;137(1):110–8, 2009.
  8. Hansen J, Snyder J, Miller E, Vandevoorde P, Miller N, Hines R, et al, Carcinoembryonic antigen (CEA) assay: a laboratory adjunct in the diagnosis and management of cancer. Hum Pathol; 5:139–47, 1974.
  9. Karkampouna S, Ten Dijke P, Dooley S, Julio MK, TGF-beta signaling in liver regeneration. Curr Pharm Des 18, 4103–4113, 2012.
  10. Johnson DG, Walker CL, Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 39: 295-312, 1999.
  11. Reitman and Frankel, A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol., 28(1):56-63, 1957.
  12. Perry B, Doumas BT, Buffone G, Glick M, Oy CN, Ryder K, Measurement of total bilirubin by use of bilirubin oxidase. Clin Chem. 32(2):329-32, 1986.
  13. Doumas BT, Watson WA, and Biggs HG, Albumin standards and the measurement of serum albumin with bromocresol green. Clin. Chim. 31: 87 – 96, 1971.
  14. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology; 38: 518–526, 2003.
  15. Sterling RK, Lissen E, Clumeck N, Sola R, Cassia Correa M, Montaner J, Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology; 43: 1317–1325, 2006.
  16. Silver K, Gold P, Feder S, Freedman O, Shuster J, Radioimmunoassay for Human Alpha-1 Fetoprotein. Proc Natl Acad Sci USA; 70(2):526–30, 1973.
  17. Hansen J, La Fontaine G, Newman S, Schwartz K, Malkin A, Mojzisik K, et al, Solving the problem of antibody interference in commercial ‘‘sandwich’’-type immunoassays of carcinoembryonic antigen. Clin Chem; 35:146–51, 1989.
  18. Derynck R, Akhurst RJ, Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol; 9(9):1000-1004, 2007.
  19. Venook AP, Papandreou C, Furuse J, Guevara LL, The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15(Suppl 4):5–13, 2010.
  20. Hussein MM, Ibrahim AA, Khattab NA, EL Fouly RF, and EL-Fouly NF, Serum transforming growth factor beta1 in hepatitis c virus related chronic liver disease and hepatocellular carcinoma patients. Med J Cairo Univ; 78:279–286, 2010.
  21. Hernandez-Castillo E, Mondragon-Sanchwz R, Garduno-Lopez AL, Gómez-Gómez E, Ruiz-Molina JM, Oñate-Ocaña LF, Bernal-Maldonado R, Hepatocellular carcinoma in the youth. A comparative analysis with hepatocellular carcinoma in adulthood. J Gastroenterol Hepatol; 52:903–907, 2005.
  22. Massoud A, Reda M, Shaker M, Detection of hepatitis B and C viruses in hepatocellular carcinoma tissue. In Liver International, 24th Biennial Meeting of the International Association for the study of the Liver (IASL) in collaboration with the African Association for the Study of Liver Diseases (AFASLD); 26:67–77, 2006.
  23. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ, Des-gamma-carboxy-prothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol; 23:1541–1548, 2008.
  24. Okonkwo UC, Nwosu MN, Nnadozie OJ, Mamah VV, Nsoedo CW, Is liver function test of any diagnostic relevance in patients presenting with hepatocellular carcinoma. Orient J Med 2011; 23:1–4, 2011.
  25. Mizejewski GJ, Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood). 226:377-408, 2001.
  26. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, Sesti R, Tripi S, Montalto G, Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 23:1747-53, 2003.
  27. Steel J, Carney M, Carr BI, Baum A, The role of psychosocial factors in the progression of hepatocellular carcinoma. Med. Hypotheses, 62: 86-94, 2004.
  28. Mayoral R, Valverde MA, Izquierdo LC, Rodríguez G A, Boscá L, Martín-Sanz P, Impairment of Transforming Growth Factor ß Signaling in Caveolin-1-deficient Hepatocytes. Role in liver regeneration. J. of Biol. Chem., 285: 3633-42, 2010.
  29. Hoshida Y, Nijman S M, Kobayashi M, Chan J A, Brunet J P, Chiang D Y, and Golub T R, Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res, 69(18), 7385-7392, 2009.
  30. El-Serag HB, Lechel A, Rudolph KL, Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. In Zakim and Boyer’s Hepatology: A Textbook of Liver Disease, 6th ed.; Boyer, T.D., Manns, M.P., Sanyal, A.J., Eds.; Saunders-Elsevier Inc.: Philadelphia, PA, USA; pp. 142–156.e4, 2012.

Publication Details

Published in : Volume 3 | Issue 2 | March-April 2017
Date of Publication : 2017-04-30
License:  This work is licensed under a Creative Commons Attribution 4.0 International License.
Page(s) : 769-774
Manuscript Number : IJSRSET1732149
Publisher : Technoscience Academy

Print ISSN : 2395-1990, Online ISSN : 2394-4099

Cite This Article :

Zahran Faten, El- Emshaty Hoda, Gouida Mona, Hussien Mohamed , " Assessment of Transforming Growth Factor β1 and DNA Cell Cycle in Egyptian Patients with Chronic Hepatitis-C Virus and Hepatocellular Carcinoma , International Journal of Scientific Research in Science, Engineering and Technology(IJSRSET), Print ISSN : 2395-1990, Online ISSN : 2394-4099, Volume 3, Issue 2, pp.769-774, March-April-2017. Citation Detection and Elimination     |     
Journal URL : https://ijsrset.com/IJSRSET1732149

Article Preview